# Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction

Study · id `cardio:ct-nct02131220` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02131220](<https://clinicaltrials.gov/study/NCT02131220>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02131220

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 362 participants.

## Technical summary

Registry record NCT02131220. Randomized; double masking; primary purpose treatment. Start 2015-11 (actual); primary completion 2017-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 362 participants (enrolled count; ClinicalTrials.gov record NCT02131220, source copy `cardio:ctgov-nct02131220-2018-08-07`, retrieved 2026-10-26)
- Started: 2015-11 (actual) (ClinicalTrials.gov record NCT02131220, source copy `cardio:ctgov-nct02131220-2018-08-07`, retrieved 2026-10-26)
- Primary completion: 2017-08 (actual) (ClinicalTrials.gov record NCT02131220, source copy `cardio:ctgov-nct02131220-2018-08-07`, retrieved 2026-10-26)
- Completion: 2017-09 (actual) (ClinicalTrials.gov record NCT02131220, source copy `cardio:ctgov-nct02131220-2018-08-07`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02131220, source copy `cardio:ctgov-nct02131220-2018-08-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02131220-2018-08-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction
- Acronym: ERUPTION
- Condition: Myocardial Infarction
- Condition: Percutaneous Coronary Intervention
- Condition: Thrombolytic Therapy
- Intervention (Drug): Prourokinase
- Intervention (Drug): Tirofiban
- Intervention (Drug): normal saline
- Lead sponsor: Fudan University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Fudan University (`cardio:org-fudan-university`)

## Provenance

Content hash: 88df6f65c29b5aaea434f41cf74a14b68e8923d445dd1ee58ded83d40683317e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
